The purpose of CIMA-Q is to promote and potentiate Québec’s expertise in research on Alzheimer’s disease. The Consortium has set up expert groups and platforms whose mission is the:
- Identification of reliable and sensitive predictive cognitive tests
- Discovery of new neuroimaging markers
- Identification of new biomarkers and therapeutic targets
- Identification of risk factors and preventive factors
Many scientific publications have already emerged from these expert groups.
Co-Investigators / Contributors : Sébastien Hébert (Ph. D.), Nicole Leclerc (Ph. D.), Edith Hamel (Ph. D.), Stephen Cunnane (Ph. D.)
The ‘biomarkers and therapeutic targets’ team provides biological materials to researchers interested in discovering new molecular mechanisms and therapeutic targets and establishing a molecular prognosis for Alzheimer’s disease. These discoveries may also help to develop new drugs that can slow progression or even cure the disease.